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Abstract  
Background  
Abdominal pain is frequently reported by people with inflammatory bowel disease (IBD), 
including in remission. Pain is an under-treated symptom.  
Aim 
To systematically review evidence on interventions (excluding disease-modifying 
interventions) for abdominal pain management in IBD. 
Methods  
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Databases (MEDLINE, EMBASE, PsycInfo, CINAHL, Scopus, Cochrane Library) were 
searched (February 2016). Two researchers independently screened references and 
extracted data.  
Results 
Fifteen papers were included: 13 intervention studies and two cross-sectional surveys. A 
variety of psychological, dietary and pharmacological interventions were reported. Four of 6 
studies reported pain reduction with psychological intervention including individualised and 
group-based relaxation, disease anxiety-related Cognitive Behavioural Therapy and stress 
management. Both psychologist-led and self-directed stress management in inactive 
Crohn’s disease reduced pain compared with controls (symptom frequency reduction index 
= -26.7, -11.3 and 17.2 at 6 month follow up, respectively). Two dietary interventions 
(alcoholic drinks with high sugar content and fermentable carbohydrate with prebiotic 
properties) had an effect on abdominal pain. Antibiotics (for patients with bacterial 
overgrowth) and transdermal nicotine patches reduced abdominal pain. Current and past 
cannabis users report it relieves pain. One controlled trial of cannabis reduced SF-36 and 
EQ-5D pain scores (1.84 and 0.7, respectively). These results must be treated with caution: 
data were derived from predominantly small uncontrolled studies of moderate to low quality. 
Conclusions  
Few interventions have been tested for IBD abdominal pain. The limited evidence suggests 
that relaxation and changing cognitions are promising, possibly with individualised dietary 
changes. There is a need to develop interventions for abdominal pain management in IBD.     
Keywords: inflammatory bowel disease, Crohn’s disease, ulcerative colitis, abdominal pain, 
pain, systematic review 
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Short title: Systematic review: IBD abdominal pain management 
Introduction 
Chronic abdominal pain is a major complaint in individuals with inflammatory bowel disease 
(IBD).1 Nevertheless, it is an under-recognised and under-treated problem with a negative 
impact on quality of life.2 There is a scarcity of research on abdominal pain in people with 
IBD. Management of abdominal pain has been recognised in Guidelines for IBD 
Management in Adults as being problematic and needing further research.3 
Pain is a frequently reported symptom in active IBD, with the expectation that in the majority 
of patients it will resolve when the disease is controlled. However, many patients also 
experience pain when IBD is in remission, although there is ambiguity regarding the definition 
of remission and its relationship with objective markers of inflammation such as inflammatory 
markers or mucosal healing. A survey conducted in the United Kingdom (UK) found that up to 
50% of patients with Crohn’s disease (CD) and 37% of those with ulcerative colitis (UC) 
reported pain, irrespective of whether IBD was in relapse or in remission.4 Of those reporting 
pain, a high level of pain (pain ≥7/10) was scored by 54% of patients with CD and 42% with 
UC.4 In a survey of people with IBD from 21 European countries (n = 4990), 62% reported 
daily pain and 28.5% reported regular analgesic use between flares.5 Only 28% reported no 
abdominal pain when IBD is in remission. In a large Swiss cross sectional survey (n=2152), 
general life quality was reported to be significantly lower (p<0.0001) in those reporting pain 
compared to those with no pain.6 
In a survey of IBD outpatients, 88% reported pain in the past week.2 The severity of pain was 
similar between genders, with slightly more women (70%) than men (65%) reporting 
abdominal pain. Of patients with UC in remission, over 50% have been found to have ongoing 
pain at least some of the time and 20% reported a moderate pain burden.7 Pain has been 
ranked by 25% of patients with UC as their most bothersome symptom.8 However, this is 
under-recognised by clinicians, many of whom report stool frequency and urgency to be most 
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bothersome to patients. 9 The presence of chronic pain, as the only presenting symptom, can 
also at times result in unnecessary exploratory surgery or a step up in medication.1 Pain 
management was in the top ten questions identified by IBD patients and clinicians to be 
addressed by research in a priority-setting exercise.10 It would seem that there are a 
considerable number of people with IBD and unmanaged pain.  
Whilst the exact origins of abdominal pain which persists despite good IBD disease control 
remain obscure, a variety of physical and psychological factors have been identified in 
previous research.11-14 The IBD inflammation-related factors may include ongoing sub-clinical 
inflammation, central and visceral post-inflammatory sensitisation, small intestinal bacterial 
overgrowth, strictures, stenosis and adhesions, food intolerances and bowel dysmotility. In 
animal models, there is strong evidence for central nervous system plasticity following gut 
inflammation, with increased neuronal excitability.15 However, low grade inflammation does 
not seem to fully explain altered perception of the gut pain as people with UC have less 
sensitivity compared to other groups, for example those with irritable bowel syndrome (IBS).16 
Pain may be modulated by central factors such as psychological symptoms (e.g. stress, 
anxiety, depression, poor coping), sleep disturbance, medications and could arise from other 
medical conditions (e.g. gallstones, renal calculi, ischaemia, neoplasia).11 In children and 
adolescents with IBD, depression often predicts abdominal pain,17 although the direction of 
the relationship is unclear. Studies in animals have found that intestinal inflammation induces 
anxiety and depression-like behaviours.18 The likely combination of factors suggest that IBD 
pain should be managed as a biopsychosocial problem.11, 18  
Abdominal pain in IBD has often been ascribed to co-existing IBS, where pain is considered 
a cardinal feature.16, 19 The overlap between IBD and IBS has proven difficult to disentangle. 
Some of the chronic abdominal pain in IBD has been reported to be due to IBS-type symptom 
patterns,20 with 35% of people in remission meeting IBS diagnostic criteria, 46% in those with 
CD, and 44% during active disease.19 In a hospital cohort, 70% of patients with IBD have been 
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found to meet criteria for IBS.21 IBS patients have shown higher scores on the Crohn’s activity 
disease index (CDAI) compared to CD patients, as abdominal pain and well-being are the 
predominant sub-scores in this measure 22. However, the Rome diagnostic criteria for IBS are 
controversial when applied to IBD, especially as they include altered bowel habit and altered 
stool consistency. In UC, brain response to visceral pain during rectal distension has been 
found to be similar to healthy controls rather than those of IBS patients, suggesting that chronic 
colonic inflammation is not necessarily associated with increased afferent input and 
hypersensitivity.23 Ascribing abdominal pain in IBD patients in remission to IBS does not help 
to relieve the pain, as interventions for IBS pain management remain largely untested in the 
presence of IBD.24 
The use of analgesics in IBD is problematic as many have the potential to exacerbate 
symptoms, cause gut-related side effects (e.g. paralytic ileus, slow motility) or mask a 
relapse.24 Some patients use opioids for pain control; however they may not have substantial 
or lasting benefit, and patients may be faced with stigma and being labelled as ‘addicted’.25 
The exact number of those using opioids for IBD pain management is unclear; however in CD, 
the proportion of opioid users for analgesia has been reported between 5% and 13%26, 27. In 
a European cohort, 14.7% of IBD patients used opioids 28. In a specialised tertiary IBD centre 
in the United States, 28% were reported to be opioid users, with women, those with more than 
two surgeries and people with depression, anxiety or a history of abuse more likely to be using 
opioids for pain relief.29 Antispasmodics may have a role in managing abdominal pain, but this 
has not been systematically studied in IBD24 and there is also a potential risk of worsening 
bowel dysmotility.11  
A  tendency to catastrophise and use emotive coping have been associated with greater pain 
severity and functional disability in both adolescents30 and adults with IBD.21 These 
dysfunctional cognitions and negative coping strategies for pain may potentially be responsive 
to modification via cognitive behavioural therapy (CBT).30 The possible under-recognition of 
the symptom of pain by clinicians, combined with patients not seeking help as they believe 
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that ‘nothing can be done’ leads to pain being under-diagnosed and not effectively managed. 
Additionally, inconsistencies and considerable variation in how pain is assessed in IBD may 
further contribute to its under-recognition and under-reporting, both in clinical practice and 
research.31  
With IBD often having an onset early in life, chronic abdominal pain may have a great illness 
burden and a negative impact on quality of life. Recognising patient reported outcomes such 
as pain is integral to improving patient quality of life, which is now routinely applied as an 
outcome measure in IBD clinical trials. 32 33 Systematic reviews have examined 
psychological interventions for the general treatment of IBD;34-36 psychological interventions 
for abdominal pain in children and adolescents (non-IBD population);37, 38 and internet 
delivered psychological therapies for the management of chronic pain in adults.39 None of 
those reviews has addressed interventions for the management of pain in IBD. As there 
were no ongoing reviews identified on the Prospero database of prospective protocols for 
systematic reviews (http://www.crd.york.ac.uk/PROSPERO), [accessed 14.03.16], this 
review was prospectively registered (ID number: 24873). 
Aims 
To provide a comprehensive review of non-disease modifying interventions for abdominal pain 
in patients with IBD. 
Methods 
A series of searches were conducted with the last search on 5 February 2016 via OVID: 
MEDLINE (1946 to Feb 2016 week 1), EMBASE (1974 to Feb 05 2016), and PsycINFO (1806 
to Feb 2016 week 1); via EBSCO: CIHAHL (05 Feb 16); and the Cochrane Library. Both 
medical subject heading (MeSH) and free-text search terms were used to maximise citation 
retrieval. The search combined two parameters: IBD (IBD, inflammatory bowel disease or 
ulcerative colitis or Crohn’s disease) and abdominal pain. Interventional studies of any design 
(randomised controlled trials (RCTs), quasi-randomised controlled trials, non-randomised 
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controlled trials, pilot and feasibility studies) and cross sectional studies were included. The 
rationale for including all study designs was based on the preliminary searches indicating that 
only limited evidence was available. Studies were excluded if their primary aim was to modify 
disease activity or if pain was reported only within a composite score (such as an IBS 
composite score) rather than reported separately (Table 1).  Our initial criteria were to include 
only studies where IBD participants were in remission. However, this yielded a very small and 
partial review, and therefore studies which included patients with active disease (or did not 
report disease status) were also included. Thus, studies where the primary aim was not to 
modify disease activity and which reported pain as a separate outcome were included, 
whether or not they reported disease activity and whether or not they included participants 
with active IBD.  
The literature search process (Figure 1) followed PRISMA guidelines.40 The retrieved 
references were imported to Endnote bibliographic software. After removing duplicates (n = 
921), 5552 citations remained. All titles were screened by CN and excluded if apparently 
irrelevant. The remaining 32 abstracts were read and assessed against the inclusion criteria 
by two researchers (CN & WCD) and three were excluded. Hand searches of the reference 
lists of identified papers provided four additional references. 
The remaining 30 papers were read in full and reviewed independently by CN & WCD. This 
resulted in 15 studies being excluded.41 Details of the excluded papers and reasons for 
exclusion are provided in an online supplementary table (Table S1). For one abstract, 42 where 
the full paper was not published, an effort was made to acquire the full text electronically from 
the author. However, as we were unable to contact the author, the abstract was excluded.  
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Figure 1: PRISMA flowchart of citation retrieval and selection process.  
Quality appraisal 
Fifteen studies were included in the review. The Critical Appraisal Skills Programme [CASP] 
assessment tools specific to the methodological design of each study (RCTs and cross-
sectional studies) were utilised to assess the studies’ quality.43 Two researchers (CN and MA 
or LS) appraised the studies independently and then agreed the final scores. Points were 
deducted if: specific objectives and hypotheses were not stated; measurement tools were not 
validated; insufficient details were provided regarding the methodology or data analysis; 
evidence of selective reporting of the findings was present; or limitations were not addressed. 
Two papers were classified as high quality,44 45 nine as medium,46-54 and four as low quality,55-
58 see Table 2. Due to the small number of retrieved citations, no studies were excluded from 
the review based on their quality. Reporting of disease activity or remission status of patients 
was absent in eight included studies.   
Total citations identified by search after 
duplicates removed 
n = 5552 
 
Total number of papers included in the 
review 
n = 15 
Studies excluded at 
abstract  
n = 6 
 
Full paper of studies read  
n =30 
Studies excluded at 
full text  
n = 15 
Studies excluded at 
title  
n = 5520 
Potentially relevant studies, abstract 
screened  
n = 32 – 6 excluded = 26 + 4 from hand 
search = 30 Hand search of 
reference list of 
included studies  
n =4 
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Results  
Of the 15 papers included in the review (Table 2), two were cross sectional surveys (n = 555 
respondents) 44, 52 and 13 were intervention studies (n = 370 total participants with IBD).45-51, 
53-58  
Three studies had a primary focus on pain, i.e. the intervention was intended specifically to 
target abdominal pain,48, 50, 55 and the remaining studies measured abdominal pain as a 
secondary outcome. The sample size of controlled trials ranged from 9 to 72. Most studies 
involved adults only, whilst in three studies the participants were adolescents as well as one 
parent per adolescent.50, 54, 55 A range of pharmacological (metronidazole, ciprofloxacin, 
transdermal nicotine, and loperamine oxide which is a prodrug for loperamide),45, 46, 58 non-
pharmacological (stress management, problem solving, cognitive coping skills, progressive 
muscle relaxation biofeedback, education on IBD),47, 50, 53-56 and dietary supplements 
(processed and unprocessed cereals, carbohydrate supplement, consumption of alcohol)48, 
51, 57 interventions were tested. Three studies reported the effect of cannabis on abdominal 
pain among other symptoms.44, 49, 52 Due to the wide array of interventions being tested, 
different research designs, outcome measures and methods of data analysis, it was not 
possible to pool the results in meta-analysis. Only 2 of the 15 included studies explicitly 
included IBD patients in remission47, 58 and eight studies did not specify disease activity 61-66 
(Table 2). These studies were included as review authors judged the study as not 
addressing pain linked to an acute disease flare.   
The results of the review are presented grouped by type of intervention and summarised in 
Table 2. 
Psychological interventions 
Six studies used psychological approaches.  
McCormick et al 49 used coping skills training (one day training plus 6 weeks of web-based 
homework and 30 minute weekly chat sessions) in a controlled intervention study. The aim 
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was to reduce pain and somatic symptoms in 24 adolescent girls with IBD plus a parent, 
allocated to intervention (n = 13) or waiting list control (n = 11). Allocation was based on 
availability to attend sessions. There was no significant difference in pain score between the 
groups after the intervention. However, the intervention group did show improvements in 
somatic symptoms and adaptive coping skills (p = 0.007). A lack of true randomisation 
precludes attributing improvements directly to the intervention. Disease activity was not 
specified. Psychosocial and disease factors associated with participation and attrition in this 
study were later investigated,59 finding that higher levels of reported abdominal pain, 
functional disability and somatic complaints were related to lower participation. As this 
second paper59 related only to attrition and not the intervention it was not included in the 
review. 
A behavioural stress management programme in 45 patients with non-active CD measured 
pain as a secondary outcome in three treatment groups: therapist-led stress management, 
self-directed stress management or control.47 Both intervention groups had reduced 
abdominal pain (p < 0.05) with improvement maintained up to 12 months in the therapist-led 
and self-directed stress management groups.   
Another study used a multi-component intervention.  Following a pilot phase (four 
participants), 23 people with IBD seeking help for stress and other symptoms including pain 
were randomised to 12 one-hour sessions of relaxation, biofeedback, cognitive coping 
strategies and education, or symptom-monitoring control.56 Both groups improved their 
abdominal pain, with the symptom monitoring control group improving by significantly more 
than the intervention group for abdominal pain and other symptoms (p < 0.01). People with 
CD had more pain at baseline than those with UC and improved by significantly more (p < 
0.001) than participants with UC, indicating a better response to treatment by CD patients. 
Shaw and Ehlrich (1987) randomised 40 UC patients with chronic pain into a group-based 
progressive relaxation intervention or a waiting list. Immediately following treatment and at 6-
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week follow up, the treatment group reported less pain, greater pain relief, fewer words to 
describe pain, less distress due to pain and less frequent pain episodes.69 
Six adolescent girls and their parents (one parent per girl) participated in a 10-session skills 
based group intervention targeting pain, coping and functional disability.55 Four of the six 
reported less pain at 6 months. 
Another cohort study involving a younger sample (11-17 years),54 examined the effects of a 
tailored CBT intervention targeting IBD-related concerns on anxiety and IBD symptoms. The 
intervention resulted in 50% of participants no longer fulfilling their principal anxiety 
diagnosis. Reductions were also seen for disease and pain severity, with pain reports 
changing from moderate to mild at post-treatment. None of these last three studies reported 
disease activity. 
Dietary interventions 
Three studies explored diet. A double-blind cross-over RCT compared processed vs. 
unprocessed cereals to decrease intestinal secretions in participants with short bowel 
syndrome; 23 of the 26 participants had IBD, but the results are not reported separately.51 
Neither intervention had an effect on abdominal pain which was not reported separately for 
IBD participants. Disease activity was not reported.  
Anecdotal reports about the exacerbation of abdominal pain and dyspepsia following 
consumption of alcohol were tested by Hey et al.48 They tested 20 people with inactive CD 
and 12 healthy controls with five alcohol challenge interventions; over fifteen minutes at two 
week intervals. Male participants consumed 36g and females 24g of alcohol. No healthy 
volunteer experienced abdominal pain; pure ethanol produced the least pain in CD 
participants, with increased pain apparently associated with drinks with a higher sugar 
content (beer and alco-pop) rather than wine.48 However, the study was small and could not 
be blinded. 
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In a cohort intervention study, 20 participants with IBD were given a fermentable 
polysaccharide supplement known to have positive prebiotic properties. Glucomannan 
hydrolysates from Konjac flour was given to participants for 14 days in an unblinded case 
series (3.3g/day high molecular weight carbohydrates for 14 days).57 Reduced abdominal 
pain was reported at day 7 and 14 (p = <0.001). The supplement was well tolerated. Disease 
status of patients was not reported.   
Pharmacological interventions 
Six studies explored pharmacological interventions. One RCT compared two antibiotics in 29 
participants with CD (with both active disease and in remission) and confirmed small bowel 
bacterial overgrowth.46 Fifteen participants reported abdominal pain before intervention and 
7/15 were improved by antibiotics, with no difference between two antibiotics. The pain score 
was improved significantly across both groups (p = 0.04). 
In another RCT, 72 participants with active UC were randomised into a transdermal nicotine 
patch or placebo group and examined the effects on symptom improvement .45 Over a 6 
week period, participants were given patches releasing 5mg or 15mg of nicotine over 16 
hours (nicotine doses were given in a stepwise manner to alleviate side effects). Abdominal 
pain was scored 0-2. Patients in the nicotine group reported significantly less abdominal pain 
compared to the placebo group (p = .05). Details of abdominal pain scoring were not 
provided. 
Loperamide oxide (initial dose 2 mg and then 1 mg after each unformed stool; mean daily 
dose 2.7 mg) was compared to placebo for one week to treat chronic diarrhoea in 34 
patients with CD.58 The investigator assessed pain and this decreased significantly with 
loperamide oxide (p = 0.02 vs. baseline) but not with placebo. Patients did not complete a 
separate pain score. Although disease activity was not specified, patients had stable 
diarrhoea symptoms. No mention was made of blinding.  
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Two cross sectional surveys reported the use of marijuana for ‘medicinal purposes’ in people 
with IBD.44, 52 In a survey of 292 IBD patients, 36 (12.3%) were current users and 114 (39%) 
were past users. Among current and past users, 16.4% felt that marijuana was very useful 
for the relief of abdominal pain. The study took place in a US state where marijuana use was 
legal for CD but not UC.52 Disease activity status was not specified. 
The second US survey of 319 IBD patients with both active and non-active disease, found 
that 17.6% reported that they had used marijuana for disease symptoms, with 83.9% of 
users reporting that it improved abdominal pain. It also had beneficial effects on abdominal 
cramping and joint pain. Cannabis use for more than six months at a time was a strong 
predictor of requiring surgery for CD patients. The authors recommended caution in the use 
of cannabis by CD patients until further studies explore effectiveness and safety.44 
Thirteen participants inhaled cannabis in a single-arm open-label pilot study.49 At baseline, 
average Harvey Bradshaw Index (HBI) scoring for patients was 11.36, indicating active 
disease, and pain was reported as severe or very severe by 10 patients. After 3 months of 
treatment one patient reported very severe pain, 4 reported severe and the remaining eight 
reported mild to moderate pain severity. Average HBI score decreased from 11.36 to 5.72, 
with main improvements seen in the domains of abdominal pain and general well-being. 
Discussion 
This is the first systematic review of interventions for abdominal pain in IBD. Pain is a 
substantial problem for many people with IBD, but despite the high prevalence, abdominal 
pain in IBD has been the subject of very few intervention studies, especially when compared 
to other long term conditions. A recent research priority setting exercise identified that pain 
needs to be further explored and methods of pain management need to be identified and 
tested.10 It is evident from this review that the types of interventions carried out for pain in 
IBD vary considerably and few have been based on an explicit theoretical model of pain in 
IBD. In addition to this, study design and methodological quality, pain outcome measure 
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utilised and measurement of disease status differ between studies. Nonetheless, it appears 
that they can be classified into physical and psychological interventions. 
Physical interventions for pain identified in this review include pharmacological treatment, 
dietary supplements and use of marijuana. Antibiotics for the treatment of small intestinal 
bacterial overgrowth46, transdermal nicotine patches 45 and loperamide oxide 58 all reported 
reduced abdominal pain. Mixed evidence was found for the effects of dietary intervention; a 
fermentable carbohydrate supplement (Glucomannan hydrolysates) reduced abdominal pain 
after a 7-day period 57 and alcoholic drinks with higher sugar content were associated with 
greater pain.48 However, an intervention investigating processed cereals and intestinal 
secretions found no effects on abdominal pain.51 One excluded study (pain outcomes were 
not reported separately) was a double-blind cross-over RCT of an Immunoglobulin G 
exclusion diet in 40 patients with active or inactive CD.60 There was no difference in a 
composite pain, general wellbeing and stool frequency score and a high drop-out rate; 
however the authors report in their abstract that abdominal pain reduced.  Dietary 
approaches similar to those used for IBS are reported anecdotally to help abdominal 
discomfort in IBD.61 Use of marijuana is reported by people with IBD as effective for 
abdominal pain 44, 52 but users are undoubtedly self-selected and may have motivation for 
reporting medicinal benefit, even where surveys are anonymised. This warrants further 
evaluation.  
There is some previous research on cognitive, emotional and behavioural factors associated 
with pain severity in IBD.21, 30 This review found a number of psychological interventions: 
both self-directed and therapist-led stress management interventions resulted in reduced 
abdominal pain 47 and a 10-week manualised programme examining cognitions, emotions, 
stress and behaviours led to less reported pain in 4 out of 6 adolescent girls.55 Integrating 
disease-specific concerns into CBT treatment also had beneficial effects in reducing pain as 
well as anxiety in a sample of children and adolescents with IBD.54 Results for a coping skills 
training intervention 50 and another multi-component behavioural treatment package 
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(including biofeedback, relaxation and cognitive coping) 56 were less promising, although 
McCormick et al.50 did find improved coping skills and fewer somatic symptoms. Schwarz 
and Blanchard 56 found that the control group intervention of symptom monitoring reported a 
greater reduction in pain than in the intervention group.  
Social learning has been suggested as a basis for treating IBD pain, incorporating elements 
of CBT, social learning and relaxation in a multi-modal intervention,62 but this approach does 
not so far seem to have been used in studies.  
Two studies considered for inclusion but excluded at the full paper stage focused on people 
with IBD with concomitant symptoms of IBS.63, 64 Both studies were excluded as no separate 
measure of pain was included, only a composite IBS score. However, these are noteworthy 
as pain is a substantial element of IBS scores. In Berrill et al.’s study of mindfulness therapy, 
no difference in IBS score at follow-up was found between 38 intervention and control 
participants who had IBS at baseline. 63  Piche et al. compared use of osteopathy with no 
intervention in 38 patients with CD who were also on 8-weekly infliximab. Severity of IBS 
symptoms was significantly improved up to day 60 in the intervention group.64 These are 
mentioned here as it would be interesting to explore interventions for IBS symptoms in IBD 
patients and measure pain directly.  
Lastly, three relevant studies were published after the database search had been carried 
out. 64, 6, 65 Volz et al’s RCT study investigated the effects of transcranial stimulation on 
reducing abdominal pain in IBD patients and significant reductions in abdominal pain, pain 
catastrophising and IBS symptom scores were found in a sample of 20 patients.65  Two 
retrospective studies of a low fermentable carbohydrate (FODMAP) diet have also reported 
pain benefits. Maagaard had responses from 40 of 109 IBD patients put on a low FODMAP 
diet a mean of 16 months previously. 63% reported that abdominal pain responded to the 
diet, but long term adherence was poor. 66 Prince et al conducted a chart review of 
symptoms in 88 IBD patients referred for low FODMAP diet, a minimum of 6 weeks after 
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referral. The proportion reporting moderate or severe abdominal pain fell from 43% to 18% 
(p<0.001). 67 
There are limitations of both the included studies and of the review. Firstly, most included 
studies were of low to medium quality, reducing the strength of evidence within this review. 
In particular, studies’ methodological limitations included small samples, high attrition rates 
and non-validated pain measures. Most studies did not specify disease status, despite most 
implying that patients were not in acute flare. This, along with the varied study design and 
intervention type, made comparability between studies’ findings difficult. Additionally, some 
studies assessed overall pain rather than abdominal pain specifically. On the other hand, 
strengths of the review lie in the transparent process of data extraction and paper screening, 
with independent researchers carrying out quality appraisal processes. 
Recommendations for clinical practice 
It is important that pain in IBD is acknowledged and assessed. While the first step is 
undoubtedly IBD disease control, clinicians should recognise that good disease control does 
not always mean that pain resolves. Proactively asking about this symptom in remission and 
then taking it seriously is important. At present, there is limited evidence to guide 
management, but referral to a dietitian or for psychological support might be considered, 
depending on patient preference and local availability.  
Recommendations for future research 
In an attempt to gain a better understanding of pain in IBD and effective treatment 
approaches, a number of recommendations for future research are presented. The use of 
better powered studies, more rigorous methodological techniques in Randomised Controlled 
Trials and the use of validated pain measures is required to strengthen evidence in this area. 
Future studies should specify pain site (e.g. abdominal, joint or other pain) and indicate 
disease status of participants. In particular, pain outcome measures should strive to address 
levels of emotional well-being, physical and social interaction, work status and overall pain 
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experience when assessing pain. Further research would be informed by research on pain in 
other chronic conditions such as inflammatory and relapsing-remitting diseases. Exploring 
the similarities and differences between abdominal pain in IBS and IBD in remission is 
important in determining whether IBS-pain interventions may be suitable for IBD. A number 
of psychotherapeutic interventions have been carried out in paediatric IBD research on 
reducing depression and disease-related outcomes which could also be informative for adult 
populations.68-70 Finally, a better understanding of the range of contributing factors to pain is 
required, to enable interventions to be designed based on sound theoretical principles. For 
example a recent paper has explored the interacting effect between pain and fatigue.71 The 
interventions considered in the included studies did not fully consider the interplay of factors 
causing pain. It is likely that a range of pharmacological, non-pharmacological and dietary 
manipulation will provide the best effects for patients, yet the interrelationship between these 
groups of factors is not well understood and needs further investigation.  
Conclusions 
Despite IBD patients’ frequent reports of chronic abdominal pain, only a few interventions 
have been tested in this population to alleviate the symptom or to improve pain perception 
and management. The current limited evidence suggests that learning to manage pain 
through relaxation or cognitive techniques may be the most promising approaches, possibly 
with some individualised dietary changes. Pharmacological treatment and marijuana use 
show some short-term benefits. This scarcity of evidence warrants further research into the 
development and testing of interventions for abdominal pain management in IBD. 
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Table 1 Inclusion and exclusion criteria for studies in the review 
Facet Inclusion 
 
Exclusion 
Population Individuals with IBD  
At least some participants reporting 
symptom of abdominal pain 
Any age 
 
We had intended originally to 
exclude participants with 
active IBD. However, it was 
not possible to apply this as 
most studies did not included a 
measure of disease activity.  
Individuals with IBD pain only 
in other locations (e.g. joint 
pain) 
Intervention Any interventional or observational 
studies seeking to improve pain or 
reporting approaches which might 
induce or provoke pain. 
Interventions may be Health Care 
Profession or patient-led.  
Medication or other 
intervention intended to induce 
or maintain IBD remission or 
reduce IBD inflammation 
Control / 
Comparison 
No comparison or any alternative 
intervention 
 
 
Outcomes Pain score, questionnaire, or 
participant evaluation of pain as a 
primary or secondary outcome 
measure 
No pain outcome reported, or 
not reported separately from 
other composite scores or 
outcome measures 
Study Design Any  Reviews, editorials, letters or 
conference abstracts (unless 
providing sufficient data to be 
included in the review)  
Key: IBD - inflammatory bowel disease 
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Table 2. Summary of included studies 
 
Author, 
design, 
reference 
Population Intervention Pain measure and 
outcomes 
Comment 
Castiglione, 
RCT, 62 
29 CD with positive 
breath test for small 
bowel bacterial 
overgrowth; 13 active 
CD, 16 in remission; 15 
with baseline 
abdominal pain 
Oral Metronidazole 250mg tds 
vs oral Ciprofloxacin 500mg 
bd both for 10 days 
Pain on 0-3 scale at one 
week later: no difference 
between groups  
Medium 
quality study  
Garcia-Vega, 
RCT, 63 
45 CD in remission A: psychologist stress 
management (relaxation, 
problem solving and coping) 
B: self-directed stress 
management (written guide + 
relaxation tape) 
C: control  
Pain scored for frequency 
and intensity. 
A & B: reduction of 
abdominal pain (both 
p<0.05). 
C: no significant change  
Maintained at 12 months 
Medium 
quality study.  
Non-
validated 
pain score 
Hayutin, 
cohort 
intervention, 
63 
2 UC, 4 CD.  
Disease activity not 
reported. 
10 weekly session manualised 
programme - cognitions, 
emotions, stress and 
behaviours 
abdominal pain index post 
treatment: 4/6 reported less 
pain. Mean pain score 
reduced. 6 months: 4/6 
reported less pain. 
Low quality 
study 
  
Hey, 
crossover 
study, 64 
20 CD in remission 
throughout the study 
period, 12 healthy 
controls.  
Alcohol consumption - 2 week 
intervals investigating effect 
of red wine, white wine, 
Smirnoff Ice, Elephant Beer 
and ethanol. 
Self-reported pain (scored 0-
3). Smirnoff Ice and 
Elephant beer resulted in 
more pain in CD (p<0.05). 
Medium 
quality study 
Lahat, open-
label pilot 
study, 65 
2 UC, 11 CD. Average 
Harvey Bradshaw Index 
score 11.36 (active 
disease) 
Inhaled cannabis treatment 
over 3 months  
SF-36, EQ-5D & Harvey 
Bradshaw Index (pain 
subscales).- After 3 months 
treatment very severe pain 
reported by 1 patient, severe 
by 4 and mild to moderate 
by the rest. 
Medium 
quality study. 
No controls, 
unblinded 
McCormick, 
RCT, 66 
13 CD, 8 UC, 3 IC. 
Disease activity not 
reported. 
Coping skills training, one day 
manualised cognitive 
behavioural intervention (6 
hours), 6-week web-based 
component homework & 
weekly 30-minute online chat.  
Abdominal pain index: no 
significant differences 
between groups on pain or 
somatic symptoms. 
Medium 
quality study 
Pagoldh, RCT, 
67 
26 short bowel 
syndrome – of which 23 
IBD: 11 UC, 12 CD. 
Disease activity not 
reported. 
Group A: diet supplement of 
processed cereals vs. Group B: 
unprocessed cereals 1g/kg 
body weight in 24 hours, 3 
daily doses. 
Self-evaluated descriptive 
survey - No difference in 
pain scores between groups  
 
 
Medium 
quality study. 
Pullan, RCT, 
45 
72 UC, active disease 
(global clinical score (0-
3) nicotine group = 1.5, 
placebo = 1.4)  
Transdermal nicotine patches 
(releasing 5 or 15mg of 
nicotine over a 16 hour 
period) vs placebo. Doses 
increased over intervention 
period for experimental group 
in stepwise manner. 
The patients in the nicotine 
group had less abdominal 
pain (p = .05). At 6 weeks 
abdominal pain (scored 0-2) 
for nicotine group = 0.3 and 
placebo group = 0.6 
High quality 
study. 
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Ravikoff 
Alegretti, 
cross-
sectional, 68 
102 UC, 177 CD, 13 IC. 
Disease activity not 
reported. 
Self-initiated marijuana use. Self-rating of pain relief - Of 
past and current users, 
32/48 reported it was very 
helpful or gave complete 
relief for abdominal pain; 
11/48 reported it as 
ineffective, or slightly or 
moderately helpful 
Medium 
quality study. 
Uncontrolled, 
self-selected 
population. 
No data on 
dose 
Reigada, 
cohort study, 
70 
9 IBD – 8 CD.  
Disease activity not 
reported. 
12 weekly individualised 
Cognitive Behavioural 
Therapy and IBD-specific 
anxiety including relaxation, 
cognitive restructuring and 
exposure exercises. 
VAS (0-8) - Reduction in 
pain symptoms was 
reported from moderate to 
mild pain symptoms from 
pre-treatment to post-
treatment. 
Medium 
quality study 
Schwarz & 
Blanchard, 
RCT, 72 
21 IBD – 10 CD, 10 UC, 
1 IC.  
Disease activity not 
reported. 
12 one-hour sessions; 
progressive muscle relaxation, 
thermal biofeedback, training 
in cognitive coping and 
education. 
Daily 8-symptom rating 
diary including abdominal 
pain on 5 point scale - Both 
groups reduced abdominal 
pain, but symptom 
monitoring control group 
reduced by more than 
intervention group.   
 
Low quality 
study. 2 
dropped out 
of control in 
RCT. 
Wait list then 
crossed over 
to 
intervention 
and 
symptoms 
worsened 
Shaw & 
Ehrlich, RCT, 
69 
40 UC with chronic pain 
for at least 6 months. 
Disease activity not 
reported. 
6 weekly 75 minute training 
sessions; progressive 
relaxation in groups of 5-8, 
with home audio tapes to 
practice at home daily. 
McGill Pain Questionnaire - 
Post treatment and 
following 6 weeks, 
treatment group showed 
less intense pain rating, 
greater pain relief, fewer 
words to describe pain, less 
distress due to pain and less 
frequent pain episodes. 
Medium 
quality study. 
Method of 
randomisatio
n unclear. Not 
blinded 
Storr, cross-
sectional, 61 
189 CD, 53 UC, 21 IC. 
Both active and inactive 
disease. Severe disease 
activity in users/non-
users = 31.1%/22.1%.  
Self-initiated cannabis use. 5 point pain score: 
0 = none 
4 = severe and preventing 
daily activities. 47/56 users 
(83.9%) reported cannabis 
helps abdominal pain. 
High quality 
study 
Suwannaporn
, cohort 
intervention, 
73 
34 IBD.  
Disease activity not 
reported. 
Glucomannan hydrolysates 
from konjac flour 3.3g in 150 
mls water daily for 14 days 
(soluble fibre and prebiotic 
properties). 
5 point pain score: 
0 = none 
4 = severe and preventing 
daily activities. Pain 
improved at day 14. 
Low quality 
study. Non-
validated 
pain score 
used 
Van Outryve 
& Touissant, 
RCT, 74 
34 CD with stabilised 
non-diarrhoeal 
symptoms.  
Disease activity not 
reported. 
Initial 2mg loperamide oxide 
and then 1 week loperamide 
oxide 1mg after each 
unformed stool, up to 
8mg/day max. 
Investigator rating 0-3. 
Investigator rated 
abdominal pain improved 
compared to baseline.  
Low quality 
study. No 
patient rating 
of outcomes. 
Abbreviations:  bd – twice a day; CD – Crohn’s disease; EQ-5D – EuroQOol; IBD – inflammatory bowel 
disease; IC – indeterminate colitis; tds –three times a day; RCT – randomised controlled trial; SF-36 – 
short form 36; UC – ulcerative colitis; VAS – visual analogue scale, NA – information not available. 
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Prisma checklist 
Section/topic  # Checklist item  
Repo
rted 
on 
page 
#  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; 
data sources; study eligibility criteria, participants, and interventions; study 
appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
2-3 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  4-7 
Objectives  4 Provide an explicit statement of questions being addressed with reference to 
participants, interventions, comparisons, outcomes, and study design (PICOS).  
7 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web 
address), and, if available, provide registration information including registration 
number.  
7 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report 
characteristics (e.g., years considered, language, publication status) used as 
criteria for eligibility, giving rationale.  
8, 
Table 
1 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, 
contact with study authors to identify additional studies) in the search and date 
last searched.  
7 
Search  8 Present full electronic search strategy for at least one database, including any 
limits used, such that it could be repeated.  
7 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in 
systematic review, and, if applicable, included in the meta-analysis).  
8 
Data collection process  1
0 
Describe method of data extraction from reports (e.g., piloted forms, 
independently, in duplicate) and any processes for obtaining and confirming data 
from investigators.  
8 
Data items  1
1 
List and define all variables for which data were sought (e.g., PICOS, funding 
sources) and any assumptions and simplifications made.  
8 
Risk of bias in individual 
studies  
1
2 
Describe methods used for assessing risk of bias of individual studies (including 
specification of whether this was done at the study or outcome level), and how 
this information is to be used in any data synthesis.  
N/A 
Summary measures  1
3 
State the principal summary measures (e.g., risk ratio, difference in means).  N/A 
Synthesis of results  1
4 
Describe the methods of handling data and combining results of studies, if done, 
including measures of consistency (e.g., I2) for each meta-analysis.  
N/A 
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Section/topic  # Reported on page #   
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative 
evidence (e.g., publication bias, selective reporting within studies).  
N/A 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup 
analyses, meta-regression), if done, indicating which were pre-specified.  
N/A 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in 
the review, with reasons for exclusions at each stage, ideally with a flow 
diagram.  
8 & 10, 
Figure 1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., 
study size, PICOS, follow-up period) and provide the citations.  
Table 2 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome 
level assessment (see item 12).  
N/A 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: 
(a) simple summary data for each intervention group (b) effect estimates 
and confidence intervals, ideally with a forest plot.  
Table 2 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals 
and measures of consistency.  
N/A 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 
15).  
N/A 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup 
analyses, meta-regression [see Item 16]).  
N/A 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each 
main outcome; consider their relevance to key groups (e.g., healthcare 
providers, users, and policy makers).  
14-18 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at 
review-level (e.g., incomplete retrieval of identified research, reporting bias).  
17 
Conclusions  26 Provide a general interpretation of the results in the context of other 
evidence, and implications for future research.  
18 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support 
(e.g., supply of data); role of funders for the systematic review.  
2 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 34 
For more information, visit: www.prisma-statement.org.  
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